small molecule

BREXAFEMME

IBREXAFUNGERP CITRATE

Loss of exclusivityJune 2039latest FDA-listed patent expiry

CompanyGlaxoSmithKline →See this company's full patent-cliff portfolio

Drug detail

Brand name	BREXAFEMME
Active ingredient	IBREXAFUNGERP CITRATE
Strength	EQ 150MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11534433	June 2039	use U-3508
10370406	January 2035	use U-3159
10927142	January 2035	substance
10174074	January 2035	substance, product
8188085	August 2030	substance, product

Regulatory exclusivity

Code	Expires
GAIN	June 2031
NCE	June 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from GlaxoSmithKline